OncoMark (Ireland)

Recent papers from OncoMark (Ireland)

1. A pipeline of machine learning-driven multi-modal data fusion methods for prognostic risk analysis in bevacizumab-treated metastatic colorectal cancerScientific Reports · 2026
2. Global variations in oncology professionals’ confidence levels for managing antibody–drug conjugate toxicities: a cross-continental surveyThe Oncologist · 2025
3. Analytical Validation of a Novel 6-Gene Signature for Prediction of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative, Early-Stage Breast CancerClinical Chemistry · 2022
4. Prognostic value of the 6-gene OncoMasTR test in hormone receptor–positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factorsEuropean Journal of Cancer · 2021
5. Combination of variations in inflammation- and endoplasmic reticulum-associated genes as putative biomarker for bevacizumab response in KRAS wild-type colorectal cancerScientific Reports · 2020
6. Advances in tissue-based imaging: impact on oncology research and clinical practiceExpert Review of Molecular Diagnostics · 2020
7. Multi-Gene Prognostic Signatures and Prediction of Pathological Complete Response to Neoadjuvant Chemotherapy in ER-Positive, HER2-Negative Breast Cancer PatientsCancers · 2020
8. Triple Combination of Ascorbate, Menadione and the Inhibition of Peroxiredoxin-1 Produces Synergistic Cytotoxic Effects in Triple-Negative Breast Cancer CellsAntioxidants · 2020
9. Low expression of pro-apoptotic proteins Bax, Bak and Smac indicates prolonged progression-free survival in chemotherapy-treated metastatic melanomaCell Death and Disease · 2020
10. Clinical Decision Support Systems in Breast Cancer: A Systematic ReviewCancers · 2020
11. A Machine Learning Platform to Optimize the Translation of Personalized Network Models to the ClinicENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) · 2019
12. Pilot study of bevacizumab in combination with docetaxel and cyclophosphamide as adjuvant treatment for patients with early stage HER-2 negative breast cancer, including analysis of candidate circulating markers of cardiac toxicity: ICORG 08–10 trialTherapeutic Advances in Medical Oncology · 2019
13. Copy number load predicts outcome of metastatic colorectal cancer patients receiving bevacizumab combination therapyNature Communications · 2018
14. Role of serum response factor expression in prostate cancer biochemical recurrenceThe Prostate · 2018
15. Assessment of concordance between fresh-frozen and formalin-fixed paraffin embedded tumor DNA methylation using a targeted sequencing approachOncotarget · 2017
16. Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanomaBMC Medicine · 2017
17. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancerOncotarget · 2017
18. A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib MalatePLoS ONE · 2017
19. Diagnostic and Therapeutic Implications of Histone Epigenetic Modulators in Breast CancerExpert Review of Molecular Diagnostics · 2016
20. Integration of genomic, transcriptomic and proteomic data identifies two biologically distinct subtypes of invasive lobular breast cancerScientific Reports · 2016